| Literature DB >> 35204877 |
Dena Nadhim Mohammad1, Ban Falih Ibraheem1, Balkees Taha Garib1, Marwa Abdul-Salam Hamied1.
Abstract
Oral and maxillofacial lesions (OMFLs) in pediatrics differ markedly from their adult counterparts in terms of clinical conduct, pathological behavior, and management. This study aims to determine the frequency of OMFLs among pediatric and adolescent patients and to correlate the demographics information to the site, and histopathological findings. Pathological records of pediatric and adolescent patients were retrieved from three major pathological centers in Sulaimani city of Iraq. Demographic information, surgical procedure, anatomical sites, and histopathological diagnosis were recorded. Furthermore, The World Health Organization (WHO) International Statistical Classification of Diseases and Related Health Problems (ICD-10) was used for coding. A Chi-square test was used to find the relation between different variables, and a p-value < 0.05 was considered statistically significant. This study archived 309 (13.3%) out of 2319 pediatric and adolescent patients, with a mean age of 11.04 ± 4.62. Females were more commonly detected (52.8%). The most frequently diagnosed lesions were salivary gland diseases (20.7%), followed by reactive hyperplastic connective tissue (18.4%). A significant relation was found between age groups and diagnostic categories (p = 0.001). The lips were the most commonly detected sites (20.7%). Mucocele was the most frequently seen non-neoplastic lesions (19.4%), followed by pyogenic granuloma (8.7%). Neoplastic lesions revealed predominant hemangioma (3.2%), followed by peripheral ossifying fibroma (1.9%). Traumatic and or reactive lesions were the most commonly reported lesions. Malignant neoplasms can be identified. The current study enabled systematic data recording of pediatric and adolescent patients, encouraging the importance of the oral healthcare system in identifying and managing the problem early in this critical age in this region.Entities:
Keywords: OMFLs; diagnosis; oral health; pediatric; reactive lesions
Year: 2022 PMID: 35204877 PMCID: PMC8870469 DOI: 10.3390/children9020156
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Distribution of the oral diagnosed lesions in response to age group, sex, and type of biopsy.
| Diagnosis Group | Age Group | Sex * | Type of Biopsy ≠ | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0–5 | 6–10 | 11–15 | 16–18 | Female | Male | Total | Incision | Excision | Inc/Excision | |
| Bone lesions | 1 | 5 | 7 | 0 | 3 | 10 | 13 (4.2%) | 2 | 9 | 2 |
| Bone tumors | 1 | 1 | 1 | 3 | 4 | 2 | 6 (1.9%) | 2 | 3 | 0 |
| Connective tissue tumors | 9 | 10 | 10 | 7 | 20 | 16 | 36 (11.6%) | 2 | 32 | 2 |
| Cystic lesions | 5 | 9 | 17 | 7 | 18 | 20 | 38 (12.4%) | 8 | 30 | 0 |
| Epithelial lesions | 2 | 1 | 0 | 3 | 3 | 3 | 6 (1.9%) | 0 | 6 | 0 |
| Hematologic neoplasm | 2 | 0 | 2 | 0 | 2 | 2 | 4 (1.4%) | 0 | 3 | 1 |
| Hematoma | 0 | 1 | 3 | 0 | 1 | 3 | 4 (1.4%) | 0 | 4 | 0 |
| Infection | 0 | 0 | 2 | 2 | 3 | 1 | 4 (1.3%) | 2 | 2 | 0 |
| Developmental anomaly | 2 | 1 | 1 | 0 | 4 | 0 | 4 (1.3%) | 0 | 4 | 0 |
| Mucocutaneous diseases | 0 | 1 | 0 | 3 | 3 | 1 | 4 (1.3%) | 2 | 2 | 0 |
| Mucositis/ulceration | 2 | 1 | 2 | 1 | 4 | 2 | 6 (1.9%) | 1 | 5 | 0 |
| Normal | 1 | 0 | 5 | 1 | 1 | 6 | 7 (2.3%) | 5 | 2 | 0 |
| Odontogenic tumors | 7 | 0 | 1 | 1 | 2 | 7 | 9 (2.9%) | 5 | 0 | 4 |
| Periapical lesions | 2 | 1 | 14 | 12 | 18 | 10 | 29 *(9.3%) | 4 | 25 | 0 |
| Periodontal diseases | 1 | 0 | 0 | 1 | 2 | 0 | 2 (0.6%) | 0 | 2 | 0 |
| Reactive hyperplasia of Lymph node | 1 | 0 | 1 | 0 | 1 | 1 | 2 (0.6%) | 0 | 2 | 0 |
| Salivary gland diseases | 7 | 21 | 33 | 3 | 36 | 28 | 64 (20.7%) | 1 | 63 | 0 |
| Salivary gland tumors | 0 | 0 | 6 | 1 | 2 | 5 | 7 (2.3%) | 0 | 7 | 0 |
| Inflammation | 1 | 1 | 0 | 0 | 1 | 1 | 2 (0.6%) | 0 | 2 | 0 |
| Reactive hyperplasia of connective tissue | 5 | 14 | 28 | 10 | 34 | 23 | 57 (18.4%) | 2 | 55 | 0 |
| epithelial tumors | 1 | 0 | 2 | 1 | 1 | 3 | 4 (1.3%) | 0 | 4 | 0 |
| Physical and chemical injury | 1 | 0 | 0 | 0 | 1 | 0 | 1 (0.3%) | 0 | 1 | 0 |
| Total | 51 (16.5%) | 67 (21.7%) | 135 (43.7%) | 56 (18.1%) | 164 (53.1%) | 144 (46.9%) | 309 (100%) | 36 (11.8%) | 263 (86%) | 9 (2.2%) |
* The sex (*) and the type of biopsy (≠) of two separate cases were not reported (consisting of 0.3% of the total cases), with Pearson Chi-Square Test: A relation was examined between the following.: age and diagnosis groups (p = 0.000), sex and diagnosis groups (p = 0.614) and type of biopsy and diagnosis groups (p = 0.000).
Figure 1Sex distribution in years 2008–2019.
Figure 2The frequency of oral and maxillofacial sites.
The distribution of the sample in response to sub-diagnosis of non-neoplastic lesions.
| Sex | Age Group | |||||||
|---|---|---|---|---|---|---|---|---|
| Diagnosis Group | Lesions | No. and % | Female | Male | 0–5 | 6–10 | 11–15 | 16–18 |
| Infection | Verrucous vulgaris | 1 (0.3%) | 1 | 0 | 0 | 0 | 1 | 0 |
| Toxoplasmosis | 1 (0.3%) | 1 | 0 | 0 | 0 | 1 | 0 | |
| Actinomycosis | 1 (0.3%) | 0 | 1 | 0 | 0 | 0 | 1 | |
| Granulomatosis | 1 (0.3%) | 1 | 0 | 0 | 0 | 0 | 1 | |
| Inflammation | Chronic sinusitis | 2 (0.6%) | 1 | 1 | 1 | 1 | 0 | 0 |
| Bone lesions | Cherubism | 1 (0.3%) | 1 | 0 | 1 | 0 | 0 | 0 |
| Central giant cell granuloma | 7 (2.2%) | 1 | 6 | 0 | 2 | 5 | 0 | |
| Osteomyelitis | 3 (0.9%) | 1 | 2 | 0 | 2 | 1 | 0 | |
| Fibrous dysplasia | 2 (0.6%) | 0 | 2 | 0 | 1 | 1 | 0 | |
| Developmental anomaly | Macroglossia | 1 (0.3%) | 1 | 0 | 1 | 0 | 0 | 0 |
| Congenital epulis | 3 (0.9%) | 3 | 0 | 1 | 1 | 1 | 0 | |
| Mucositis | Non-specific ulcer | 6 (1.9%) | 4 | 2 | 2 | 1 | 2 | 1 |
| Normal tissue | Normal | 7 (2.3%) | 1 | 6 | 1 | 0 | 5 | 1 |
| Mucocutaneous diseases | Pemphigus vulgaris | 2 (0.6%) | 2 | 0 | 0 | 0 | 0 | 2 |
| Lichen planus | 1 (0.3%) | 1 | 0 | 0 | 0 | 0 | 1 | |
| Lichenoid reaction | 1 (0.3%) | 0 | 1 | 0 | 1 | 0 | 0 | |
| Cystic lesions | Kerato-odontogenic cyst | 11 (3.5%) | 3 | 8 | 0 | 1 | 7 | 3 |
| Aneurysmal bone cysts | 4 (1.3%) | 4 | 0 | 2 | 0 | 0 | 2 | |
| Dentigerous cysts | 10 (3.2%) | 1 | 9 | 0 | 5 | 5 | 0 | |
| Developmental cysts * | 7 (2.2%) | 5 | 2 | 1 | 2 | 4 | 0 | |
| Dermoid-Epidermoid cysts | 4 (1.2%) | 3 | 1 | 2 | 1 | 0 | 1 | |
| Eruption cysts | 1 (0.3%) | 1 | 0 | 0 | 0 | 1 | 0 | |
| Calcifying odontogenic cyst | 1 (0.3% | 1 | 0 | 0 | 0 | 0 | 1 | |
| Periapical lesions | Granuloma | 6 (1.9%) | 4 | 2 | 0 | 0 | 4 | 2 |
| Abscess | 2 (0.6%) | 2 | 0 | 1 | 1 | 0 | 0 | |
| Periapical cyst | 21 (6.8%) ≠ | 12 | 8 | 1 | 0 | 10 | 10 | |
| Reactive hyperplasia of LN | Reactive hyperplasia of Lymph nodes | 2 (0.6%) | 1 | 1 | 1 | 0 | 1 | 0 |
| Periodontal diseases | Chronic gingivitis | 1 (0.3%) | 1 | 0 | 1 | 0 | 0 | 0 |
| Gingival fibromatosis | 1 (0.3%) | 1 | 0 | 0 | 0 | 0 | 1 | |
| Salivary gland diseases | Mucocele | 60 (19.4%) | 35 | 25 | 7 | 20 | 30 | 3 |
| Chronic sialadenitis | 2 (0.6%) | 0 | 2 | 0 | 0 | 2 | 0 | |
| Benign lymphoepithelial lesions | 1 (0.3%) | 1 | 0 | 0 | 0 | 1 | 0 | |
| Acute sialadenitis | 1 (0.3%) | 0 | 1 | 0 | 1 | 0 | 0 | |
| Reactive hyperplasia of connective tissue | Pyogenic granuloma | 27 (8.7%) | 18 | 9 | 2 | 7 | 13 | 5 |
| Peripheral giant cell granuloma | 16 (5.2%) | 8 | 8 | 2 | 4 | 8 | 2 | |
| Fibro-epithelial polyp | 14 (4.6%) | 8 | 6 | 1 | 3 | 7 | 3 | |
| Physical and chemical injuries | Eosinophilic granuloma | 1 (0.3%) | 1 | 0 | 1 | 0 | 0 | 0 |
| Hematoma | Hematoma | 4 (1.3%) | 1 | 3 | 0 | 1 | 3 | 0 |
| Epithelial lesions | Hyperkeratosis | 2 (0.6%) | 1 | 1 | 0 | 1 | 0 | 1 |
| Hyperplasia | 2 (0.6%) | 0 | 2 | 2 | 0 | 0 | 0 | |
| Intradermal nevus | 1 (0.3%) | 1 | 0 | 0 | 0 | 0 | 1 | |
| Dysplasia | 1 (0.3%) | 1 | 0 | 0 | 0 | 0 | 1 | |
| Total = 243 (78.6%) | ||||||||
* Developmental cysts included (5 thyroglossal duct cyst, 1 branchial cleft cyst, 1 inflamed cyst). ≠ sex of one periapical cyst lesion was not reported.
The distribution of the sample in response to sub-diagnosis of neoplastic lesions.
| Sex | Age Group | |||||||
|---|---|---|---|---|---|---|---|---|
| Diagnosis Group | Lesions | No. and % | Female | Male | 0–5 | 6–10 | 11–15 | 16–18 |
| Bone tumor | Ossifying fibroma | 2 (0.6%) | 1 | 1 | 1 | 0 | 0 | 1 |
| Osteochondroma | 1 (0.3%) | 1 | 0 | 0 | 0 | 0 | 1 | |
| Osteoma | 1 (0.3%) | 1 | 0 | 0 | 0 | 0 | 1 | |
| Osteosarcoma | 1 (0.3%) | 1 | 0 | 0 | 1 | 0 | 0 | |
| Ewing’s sarcoma | 1 (0.3%) | 0 | 1 | 0 | 0 | 1 | 0 | |
| Hematologic neoplasms | Burkitt’s lymphoma | 1 (0.3%) | 1 | 0 | 1 | 0 | 0 | 0 |
| Lymphoma | 1 (0.3%) | 0 | 1 | 0 | 0 | 1 | 0 | |
| Langerhans cell histiocytosis X | 2 (0.6%) | 1 | 1 | 1 | 0 | 1 | 0 | |
| Connective tissue tumors | Hemangiopericytoma | 3 (0.9%) | 1 | 2 | 1 | 1 | 1 | 0 |
| Nodular fasciitis | 3 (0.9%) | 2 | 1 | 3 | 0 | 0 | 0 | |
| Hemangioma | 10 (3.2%) | 5 | 5 | 2 | 2 | 3 | 3 | |
| Cystic hygroma | 2 (0.6%) | 2 | 0 | 1 | 0 | 1 | 0 | |
| Neural tumor | 3 (0.9%) | 0 | 3 | 1 | 0 | 2 | 0 | |
| Lymphangioma | 3 (0.9%) | 2 | 1 | 0 | 2 | 0 | 1 | |
| Lipoma | 1 (0.3%) | 1 | 0 | 0 | 1 | 0 | 0 | |
| Fibroma | 1 (0.3%) | 1 | 0 | 0 | 1 | 0 | 0 | |
| Peripheral ossifying fibroma | 6 (1.9%) | 6 | 0 | 0 | 1 | 3 | 2 | |
| Lymphangioma-hemangioma | 2 (0.6%) | 0 | 2 | 0 | 2 | 0 | 0 | |
| Rhabdomyosarcoma | 2 (0.6%) | 0 | 2 | 1 | 0 | 0 | 1 | |
| Salivary gland tumors | Pleomorphic adenoma | 4 (1.3%) | 2 | 2 | 0 | 0 | 3 | 1 |
| Mucoepidermoid carcinoma | 3 (1%) | 0 | 3 | 0 | 0 | 3 | 0 | |
| Epithelial tumors | Squamous papilloma | 3 (1%) | 1 | 2 | 1 | 0 | 1 | 1 |
| Melanoma | 1 (0.3%) | 0 | 1 | 0 | 0 | 1 | 0 | |
| Odontogenic tumors | Ameloblastic fibroma | 3 (1%) | 0 | 3 | 3 | 0 | 0 | 0 |
| Ameloblastoma | 1 (0.3%) | 1 | 0 | 1 | 0 | 0 | 0 | |
| Odontoma | 2 (0.6%) | 0 | 2 | 1 | 0 | 0 | 1 | |
| Odontogenic fibroma | 1 (0.3%) | 0 | 1 | 0 | 0 | 1 | 0 | |
| Melanotic neuroectodermal tumor | 2 (0.6%) | 1 | 1 | 2 | 0 | 0 | 0 | |
| Total = 66 (21.4%) | ||||||||
The distribution of malignant lesions in terms of age and sex.
| Malignancies | Age Group | Sex | ||||
|---|---|---|---|---|---|---|
| 0–5 | 6–10 | 11–15 | 16–18 | Female | Male | |
| Osteosarcoma | 0 | 1 | 0 | 0 | 1 | 0 |
| Ewing’s sarcoma | 0 | 0 | 1 | 0 | 0 | 1 |
| Burkitt’s lymphoma | 1 | 0 | 0 | 0 | 1 | 0 |
| Lymphoma | 0 | 0 | 1 | 0 | 0 | 1 |
| Melanoma | 0 | 0 | 1 | 0 | 0 | 1 |
| Mucoepidermoid | 0 | 0 | 3 | 0 | 0 | 3 |
| Rhabdomyosarcoma | 1 | 0 | 0 | 1 | 0 | 2 |
| Total 10 (3%) | 2 (0.6%) | 1 (0.3%) | 6 (1.8%) | 1 (0.3%) | 2 (0.6%) | 8 (2.4%) |